Back to Journals » Vascular Health and Risk Management » Volume 3 » Issue 5

Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia

       
Total article views   HTML views PDF downloads Totals
6,342 Dovepress* 6,342+ 2,598 8,940
Totals 6,342 2,598 8,940
*Since 15 November 2007
+Since July 2016

View citations on Google Scholar